Gene therapy-focused CDMO Forge Biologics has closed on a $120 million Series B financing, saying the proceeds will accelerate its planned expansion of adeno-associated virus (AAV) manufacturing capabilities.
The company operates a 175,000-square-foot cGMP facility in Columbus, OH, dedicated to AAV viral vector manufacturing, which the company has nicknamed “The Hearth.”
“Forge will use these proceeds to speed up the expansion of our buildout in Columbus,” Timothy J. Miller, PhD, Forge’s CEO, president, and co-founder, told GEN. “We will be expanding existing AAV manufacturing capabilities with additional FDA- and [European Medicines Agency] EMA-compliant GMP commercial suites in the next 12–18 months.”
